Racura Oncology recently raised AU$34.3 (US$24.31) million to fund its RC220 clinical programmes in acute myeloid leukaemia (AML), epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer, and anthracycline cardioprotection in solid tumour patients. Diana Turner speaks to Dr Peter Smith, Executive Chair of Racura, about the company’s approach to suppressing an ‘undruggable’ target […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!